Literature DB >> 8048437

Principles and practice of case mix adjustment: applications to end-stage renal disease.

S Greenfield1, L Sullivan, R A Silliman, K Dukes, S H Kaplan.   

Abstract

For optimal case mix adjustment, it is necessary to build risk or severity models to fit the disease and its outcome. For cardiac disease, for example, several risk models predict the outcome of mortality. These risk models include variables that, by themselves in multivariable models, predict death. If a variable is associated with death independent of treatment or quality of care, it has to be adjusted for and, therefore, included in the model. Similar models have to be developed and tested for end-stage renal disease. A complete risk model would consist of age, sex, the severity of the primary disease of interest (here, end-stage renal disease), not just the presence but also the severity of all co-morbid disease, and, finally, a measurement of functional status or quality of life. This last measurements is associated with outcome beyond and independent of the above noted severity components. These factors (or "severity" or "patient mix" dimensions) then have to be developed in relation to a specific outcome or response variable. Cholesterol and hypertension are risk factors for long-term events and mortality, but not for 2-year symptoms and quality of life. Thus, the model has to be defined by the type of outcome and by the time interval over which the variable acts. For end-stage renal disease, at least one of the major types of outcome will be quality of life. Our case mix measures for hospital co-morbidity and for office practice chronic disease are defined by and intended to predict functional status in the short run, because that is the outcome of interest for dollars spent and for most of the care rendered to patients with chronic disease before the very end stages. Creating a valid case mix or severity measurement aimed at or defined by quality of life thus involves the creation of new models, the testing of those models, the revision based on the empirical testing, and, finally, generalizing to other sites beyond which the data were collected. Useful case mix measurements will be parsimonious, feasible, reliable, validated against the outcome of interest, shown to work in diverse settings, and acceptable to users, especially clinicians.

Entities:  

Mesh:

Year:  1994        PMID: 8048437     DOI: 10.1016/s0272-6386(12)80195-8

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  6 in total

1.  Benchmarking physical therapy clinic performance: statistical methods to enhance internal validity when using observational data.

Authors:  Linda Resnik; Dawei Liu; Dennis L Hart; Vince Mor
Journal:  Phys Ther       Date:  2008-08-08

2.  Updated comorbidity assessments and outcomes in prevalent hemodialysis patients.

Authors:  Tara I Chang; Jane Paik; Tom Greene; Dana C Miskulin; Glenn M Chertow
Journal:  Hemodial Int       Date:  2010-10       Impact factor: 1.812

3.  Weighted index explained more variance in physical function than an additively scored functional comorbidity scale.

Authors:  Linda Resnik; Pedro Gozalo; Dennis L Hart
Journal:  J Clin Epidemiol       Date:  2010-08-16       Impact factor: 6.437

4.  Phosphate levels and blood pressure in incident hemodialysis patients: a longitudinal study.

Authors:  Cindy Xin Huang; Laura C Plantinga; Nancy E Fink; Michal L Melamed; Josef Coresh; Neil R Powe
Journal:  Adv Chronic Kidney Dis       Date:  2008-07       Impact factor: 3.620

5.  Comparisons of quality of life between patients underwent peritoneal dialysis and hemodialysis: a systematic review and meta-analysis.

Authors:  Anan Chuasuwan; Siriporn Pooripussarakul; Ammarin Thakkinstian; Atiporn Ingsathit; Oraluck Pattanaprateep
Journal:  Health Qual Life Outcomes       Date:  2020-06-18       Impact factor: 3.186

6.  Validating a Patient-Reported Comorbidity Measure with Respect to Quality of Life in End-Stage Renal Disease.

Authors:  Maxi Robinski; Franz Strich; Wilfried Mau; Matthias Girndt
Journal:  PLoS One       Date:  2016-06-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.